- PR Newswire•4 hours ago
INTUNIV® (Guanfacine Hydrochloride Prolonged Release), a Non-stimulant for the Treatment of ADHD, Receives Approval in Japan
Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that its partner in Japan, Shionogi & Co., Ltd, has received the approval of the Japanese Ministry of Health, Labor and Welfare to manufacture and market INTUNIV. INTUNIV is a selective alpha-2A adrenergic receptor agonist. With a unique mechanism of action, INTUNIV represents an additional treatment option in the management of ADHD.
- Barrons.com•3 days ago
Gimme Credit is taking drug maker Shire (SHPG) to task today, but not for the load of debt it piled onto its once pristine balance sheet when it acquired U.S. drug make Baxalta last year. Rather, analyst Carol Levenson complains that while company has made progress paying down its management still doesn’t know how to talk to bond investors. According to Levenson, Shire, which unveiled terms of its $32 billion purchase of the Baxter (BAX) spinoff in January 2016, has never released detailed plans for deleveraging its balance sheet.
- Zacks•7 days ago
Shire plc (SHPG) announced that the FDA has granted Fast Track designation for recombinant ADAMTS13 (SHP655) for the treatment of acute episodes of hereditary thrombotic thrombocytopenic purpura (hTTP).
SHPG : Summary for Shire plc - Yahoo Finance
Shire plc (SHPG)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||178.25 x 200|
|Ask||178.35 x 400|
|Day's Range||176.17 - 178.47|
|52 Week Range||161.09 - 209.22|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||143.47|
|Dividend & Yield||0.91 (0.51%)|
|1y Target Est||N/A|